Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1988-7-11
|
pubmed:abstractText |
Monoclonal antibody MOv2, produced against ovarian carcinoma, was previously found to bind a carbohydrate epitope (CAMOv2) present on mucins, glycoproteins and a neutral glycolipid. In this paper, the structure of the carbohydrate epitope is determined by immunological reactivity with purified glycolipids and oligosaccharides. Using solid-phase radioimmunoassay and immunostaining of thin layer chromatograms, MOv2 binds strongly to Le(a)-active pentasaccharide ceramide. A smaller neutral glycolipid also weakly binds MOv2. Fifty percent inhibition of binding to Le(a)-active pentasaccharide ceramide is achieved with approximately 8 microM concentration of lacto-N-fucopentaose II (LNF II). Lacto-N-tetraose (LNT) also partially inhibits at about 10(3) times higher concentration suggesting that the faster migrating glycolipid antigen contains this carbohydrate sequence. Binding to Le(a)-active hapten is further confirmed by the specific inhibition of binding by authentic anti-Le(a) monoclonal antibodies but not by anti-Le(b) MOv2 antibody in a serum assay among healthy blood donors also supports these results. In conclusion, we have obtained direct evidence from several independent experiments that antibody MOv2 recognizes the Le(a)-active hapten.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Carbohydrates,
http://linkedlifedata.com/resource/pubmed/chemical/Glycolipids,
http://linkedlifedata.com/resource/pubmed/chemical/Haptens,
http://linkedlifedata.com/resource/pubmed/chemical/Lewis Blood-Group System,
http://linkedlifedata.com/resource/pubmed/chemical/Oligosaccharides
|
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0272-457X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
7
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
129-39
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:3372000-Antibodies, Monoclonal,
pubmed-meshheading:3372000-Antibodies, Neoplasm,
pubmed-meshheading:3372000-Antigens,
pubmed-meshheading:3372000-Binding, Competitive,
pubmed-meshheading:3372000-Carbohydrates,
pubmed-meshheading:3372000-Female,
pubmed-meshheading:3372000-Glycolipids,
pubmed-meshheading:3372000-Haptens,
pubmed-meshheading:3372000-Humans,
pubmed-meshheading:3372000-Lewis Blood-Group System,
pubmed-meshheading:3372000-Oligosaccharides,
pubmed-meshheading:3372000-Ovarian Cysts,
pubmed-meshheading:3372000-Ovarian Neoplasms
|
pubmed:year |
1988
|
pubmed:articleTitle |
The antitumor monoclonal antibody MOv2 recognizes the Lewis A hapten.
|
pubmed:affiliation |
Division of Experimental Oncology E Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|